2012-11-13 05:37:02 - Menarini Group, The - SWOT, Strategy and Corporate Finance Report - a new company profile report on companiesandmarkets.com

Menarini Group, The - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company´s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company.

Features:

- Detailed information on Menarini Group, The required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Menarini Group, The in the form of a SWOT analysis
- An in-depth view of the business model of Menarini Group, The including a breakdown and examination of key business segments
- Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Menarini Group, The
-

 

 

Intelligence on Menarini Group, Thenv´s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Menarini Group, The, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

The Menarini Group (Menarini) is the largest pharmaceutical company in Italy. This privately held group is engaged in the development and manufacture of pharmaceutical products mainly for cardiovascular diseases, oncology, and pain, inflammation and asthma. Menarini has established a presence throughout Europe, Latin America, Asia, and Africa. The group is headquartered in Florence, Italy and employed 12,890 people at the end of the year 2010. The group recorded revenues of E3,031 million (4,021.2 million*) during the financial year (FY) ended December 2010, an increase of 8.4% over FY2009. Menarini has not provided other financial data including operating and net profits. * Calculated using the constant currency conversion rate of E1 = $1.3267 for the financial year ended December 31, 2010.
Reasons to Purchase:

- Gain understanding of Menarini Group, The and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess Menarini Group, The as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers´ businesses better
- Stay up to date on Menarini Group, The´s business structure, strategy and prospects

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Company Profile Reports www.companiesandmarkets.com/Market/All/Company-Profile?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.